CSO Mark Reed attended the 7th World CNS Summit in Boston, Massachusetts. This industry-focused event is aimed at fostering translational neurodegenerative research and inspiring drug discovery for neurodegenerative disorders. Dr. Reed spoke with companies in the neurodegenerative space about the Treventis approach to protein misfolding therapeutics.